Article and Video CATEGORIES

Cancer Journey

Search By

Sandip Patel, MD, is a board-certified medical oncologist who specializes in cancer immunotherapy and early phase clinical trials involving immunotherapy across all types of cancer. Dr. Patel is focused on developing personalized therapies that stimulate a patient’s immune system to attack their specific tumor. He believes in offering these promising immunotherapeutics across all tumor types. 

Targeted Therapies Forum Presented in English 2023 - Q&A Video Series 2
Our Targeted Therapies Forum online event includes a Q&A session where our amazing faculty answers questions from the audience. This is the second batch of videos for our Q&A session.
Author
Sandip P. Patel, MD, GRACE Faculty
Image
Targeted Therapies Forum presented in English

In this series of videos from the Q&A sessions, the following videos are available for viewing:

  • Q&A: Should Biomarker Testing Be Performed on Patients with Squamous Cell Carcinoma?
  • Resistance on Targeted Therapy: Questions Patients Should Ask
  • What Are Some Local Therapy Options for Patients with NSCLC?
  • Q&A: What Can Patients Do to Close the Biomarker Testing Gap?
  • Q&A: What Do We Know About Prevention and Causes of Lung Cancer?

To watch the complete playlist click here.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.